COEP Stock - Coeptis Therapeutics, Inc.
Unlock GoAI Insights for COEP
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | $75,000 | $30,761 |
| Gross Profit | $-1,038,632 | $-1,001,236 | $-1,001,384 | $75,000 | $-933,456 |
| Gross Margin | N/A | N/A | N/A | 100.0% | -3034.5% |
| Operating Income | $-10,054,488 | $-21,491,125 | $-34,195,964 | $-14,045,932 | $-6,861,403 |
| Net Income | $-10,877,412 | $-21,266,537 | $-37,574,217 | $-13,449,280 | $-9,156,286 |
| Net Margin | N/A | N/A | N/A | -17932.4% | -29765.9% |
| EPS | $-5.65 | $-0.83 | $-2.87 | $-13.16 | $-0.45 |
Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.
Visit WebsiteEarnings History & Surprises
COEPEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 13, 2025 | — | $-0.58 | — | — |
Q3 2025 | Aug 14, 2025 | — | $-1.17 | — | — |
Q2 2025 | May 14, 2025 | — | $-1.11 | — | — |
Q1 2025 | Mar 28, 2025 | $-0.80 | $-1.01 | -26.5% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-0.05 | $-0.05 | 0.0% | = MET |
Q3 2024 | Aug 16, 2024 | $-0.09 | $-0.08 | +11.1% | ✓ BEAT |
Q2 2024 | May 10, 2024 | — | $-0.08 | — | — |
Q1 2024 | Mar 26, 2024 | — | $-0.11 | — | — |
Q4 2023 | Nov 9, 2023 | — | $-0.23 | — | — |
Q3 2023 | Aug 11, 2023 | $-0.12 | $-0.08 | +33.3% | ✓ BEAT |
Q2 2023 | May 15, 2023 | — | $-0.46 | — | — |
Q1 2023 | Mar 29, 2023 | — | $-0.20 | — | — |
Q4 2022 | Nov 18, 2022 | — | $-0.28 | — | — |
Q3 2022 | Aug 2, 2022 | — | $-0.48 | — | — |
Q2 2022 | May 12, 2022 | — | $-166751.73 | — | — |
Q1 2022 | Mar 11, 2022 | — | $-0.30 | — | — |
Q4 2021 | Nov 15, 2021 | — | $-0.29 | — | — |
Q3 2021 | Aug 16, 2021 | — | $-0.13 | — | — |
Q2 2021 | May 18, 2021 | — | $-0.10 | — | — |
Q1 2021 | Jan 11, 2021 | — | $-302.02 | — | — |
Latest News
Frequently Asked Questions about COEP
What is COEP's current stock price?
What is the analyst price target for COEP?
What sector is Coeptis Therapeutics, Inc. in?
What is COEP's market cap?
Does COEP pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to COEP for comparison